about
Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women.Changes in cell proliferation, but not in vascularisation are characteristic for human endometrium in different reproductive failures--a pilot study.Anti-Müllerian hormone and progesterone levels produced by granulosa cells are higher when derived from natural cycle IVF than from conventional gonadotropin-stimulated IVF.Fertility preservation for non-medical reasons: controversial, but increasingly common.Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT.Twenty years' experience with the Swiss data registry for assisted reproductive medicine: outcomes, key trends and recommendations for improved practice.Oral contraception does not alter single dose saquinavir pharmacokinetics in womenFertility preservation in women with malignant tumors and gonadotoxic treatments.Immunology of human endometrium.Implantation of the human embryo: research lines and models. From the implantation research network 'Fruitful'.Follicle flushing in monofollicular in vitro fertilization almost doubles the number of transferable embryosRecurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG (S1-Level, AWMF Registry No. 015/050, December 2013).GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.Exogenous gonadotropins do not increase the blood-follicular transportation capacity of extra-ovarian hormones such as prolactin and cortisol.Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy--a technique in its infancy but already successful in fertility preservation.Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network.Ultra-low dose - new approaches in menopausal hormone therapy.State of the art: Reproduction and pregnancy in rheumatic diseases.Fertility preservation options in breast cancer patients.Characteristics and attitudes of women in relation to chosen fertility preservation techniques: a prospective, multicenter questionnaire-based study with 144 participants.Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations.Endometrial interleukin-6 in vitro is not regulated directly by female steroid hormones, but by pro-inflammatory cytokines and hypoxia.GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients.Proteins in the extraembryonic matrix of preimplantation rabbit embryos.Evidence for cycle-dependent expression of full-length human chorionic gonadotropin/luteinizing hormone receptor mRNA in human endometrium and decidua.Glucose transporter proteins (GLUT) in human endometrium: expression, regulation, and function throughout the menstrual cycle and in early pregnancy.Cell-type specific expression and regulation of apolipoprotein D and E in human endometrium.Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation.Galectin fingerprinting in human endometrium and decidua during the menstrual cycle and in early gestation.Fertility preservation in >1,000 patients: patient's characteristics, spectrum, efficacy and risks of applied preservation techniques.Galectin-9: a new endometrial epithelial marker for the mid- and late-secretory and decidual phases in humans.Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor.Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial.The long pentraxin PTX3 in human endometrium: regulation by steroids and trophoblast products.Treatment-related psychological stress in different in vitro fertilization therapies with and without gonadotropin stimulation.Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques.A role for "acquired" activated protein C resistance in recurrent fetal loss?Serum but not follicular fluid cytokine levels are increased in stimulated versus natural cycle IVF: a multiplexed assay study.Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF.Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma--evaluation by using antimüllerian hormone and retrieved oocytes.
P50
Q30994118-BE0025AF-111A-4BEE-9C0C-4685A5364461Q33995983-A9422DAA-BCF3-4176-B01F-4A1B32E0222EQ34472471-F1B34BD6-99ED-437E-8754-B3AFE36E5AAFQ35062457-7F6567C1-8E8A-4E9B-8754-C4CB06F566EDQ35097386-C159CA34-FE60-4DA3-82EB-F3B46E6108ECQ35558804-2C693B06-2D3A-40B7-B8FA-A0F2A3988615Q35825971-9A745CBD-E1C8-4F41-A52A-BB126B0EF99FQ35896408-A27ACF83-D721-4A9C-B983-2178C5080324Q35965729-0F5B7901-7C3C-4B23-A48D-F77C0E12324EQ36512065-F7991588-4559-4253-8A5D-FFAF8B2493E5Q36682318-5899FF6E-09F8-4ABA-8E77-1E08B2837F84Q36697714-B8468643-3AF9-4E37-BFE7-49B24C550C73Q37282095-7903F708-014F-4958-87B3-D6C8015641EDQ37358148-597B292D-9250-4AB1-8A25-68402D4FC421Q37407512-9DB207A6-B2A6-4721-A5FD-452225213434Q37995966-0DC2F5EA-4824-4E4B-8E81-C5F3F5B16F14Q38261770-D012FD13-27C2-4E41-AE36-E718041B4A88Q38306264-E002E435-D9E7-442C-BADF-A3957E5D20D6Q38586785-31A8C4D1-E390-4A84-819C-BC97095AF979Q38886721-0420A6AF-870B-4E7D-BC75-2674536AE5F8Q39958952-179BDB19-1A57-4AFC-B1C6-43FBA0118058Q40685168-CC6AD500-1B31-4295-B49A-E2585C6035EAQ43228351-AC59C749-3661-4C9D-9494-22D01647CDB0Q44246342-229EC348-9F58-4181-8128-9675A1BEDD0CQ44349551-7BE9F862-5893-4024-8C4F-7C060EB4D26AQ44547583-70670F0E-8AA5-4546-8278-EFAC01775480Q44615761-2E7F86AA-5229-4F69-BE47-F9E2C80AF97EQ44992420-F9723C17-DDD4-404C-A282-2ED51A8786D4Q45244862-EC89C6F5-6FDC-4A6D-BE82-7CA2642CC6FCQ46590938-A0916816-13DB-488D-98A1-2327BFFC5FACQ46655062-72B37D0C-0B4A-471E-8B1F-3C6391132F03Q46841144-1981972D-30C5-4730-B22D-69C9C3D40650Q46849859-52903BED-E917-4C87-A47E-603C006BDD71Q46874544-00BCCE4A-9B6B-45D1-8497-84008C0A53E9Q47220194-F5C14A93-A5F5-40C6-B475-E72002BADEF6Q47404500-1D681053-D4CF-4A79-97A5-A3C94089164BQ47623714-46924CC5-0D5A-425A-9F64-692EFFFD7A4EQ48596586-63F33F0B-8C40-4450-833C-02C0F4ED83CBQ48607037-F19A46F2-399E-43F8-B29C-F394425A77A3Q48648680-BAB72AE5-5557-439C-BD4C-7190650BC1B9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael von Wolff
@ast
Michael von Wolff
@en
Michael von Wolff
@es
Michael von Wolff
@nl
Michael von Wolff
@sl
type
label
Michael von Wolff
@ast
Michael von Wolff
@en
Michael von Wolff
@es
Michael von Wolff
@nl
Michael von Wolff
@sl
prefLabel
Michael von Wolff
@ast
Michael von Wolff
@en
Michael von Wolff
@es
Michael von Wolff
@nl
Michael von Wolff
@sl
P106
P1153
6701654784
P21
P31
P496
0000-0003-4303-2734